CSL Limited (OTCMKTS:CSLLY – Get Free Report) was the recipient of a significant growth in short interest in the month of February. As of February 28th, there was short interest totalling 20,000 shares, a growth of 189.9% from the February 13th total of 6,900 shares. Based on an average daily volume of 216,000 shares, the short-interest ratio is presently 0.1 days. Currently, 0.0% of the company’s stock are sold short.
CSL Stock Up 1.6 %
CSLLY traded up $1.24 during trading on Friday, hitting $79.39. 79,327 shares of the company traded hands, compared to its average volume of 85,486. CSL has a one year low of $77.37 and a one year high of $109.00. The stock’s fifty day moving average is $84.05 and its 200 day moving average is $91.43. The company has a debt-to-equity ratio of 0.58, a current ratio of 2.18 and a quick ratio of 0.97.
Wall Street Analyst Weigh In
Separately, The Goldman Sachs Group upgraded CSL to a “strong-buy” rating in a report on Thursday, January 16th.
CSL Company Profile
CSL Limited researches, develops, manufactures, markets, and distributes biopharmaceutical and vaccines in Australia, the United States, Germany, the United Kingdom, Switzerland, China, Hong Kong, and internationally. The company operates through CSL Behring, CSL Seqirus, and CSL Vifor segments. The CSL Behring segment offers plasma products, gene therapies, and recombinants.
Featured Stories
- Five stocks we like better than CSL
- How to Invest in the Best Canadian Stocks
- Casey’s Uptrend Remains Strong—New Highs on the Horizon
- P/E Ratio Calculation: How to Assess Stocks
- Taiwan Semiconductor’s Huge U.S. Move—Stock Impact Ahead
- Stock Sentiment Analysis: How it Works
- Why Costco Stock Is Poised to Hit $1,000 Again Soon
Receive News & Ratings for CSL Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CSL and related companies with MarketBeat.com's FREE daily email newsletter.
